MedTrace Logo

Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32

NCT01666171 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 458

Last updated 2013-07-10

No results posted yet for this study

Summary

RATIONALE: Learning about the effect of metformin hydrochloride in breast density of women with early-stage breast cancer may help plan treatment.

PURPOSE: This trial studies changes in breast density in patients with early-stage breast cancer treated with metformin hydrochloride or placebo on CAN-NCIC-MA.32.

Conditions

Interventions

DRUG

metformin hydrochloride

OTHER

clinical observation

OTHER

diagnostic laboratory biomarker analysis

OTHER

imaging biomarker analysis

OTHER

medical chart review

PROCEDURE

digital mammography

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Cancer and Leukemia Group B

    lead NETWORK

Principal Investigators

  • Marie E. Wood, MD · University of Vermont

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01666171 on ClinicalTrials.gov